Introduction: In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited.
Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has received approval from the FDA for an additional indication...
The FDA has approved Lenvima (lenvatinib), from Eisai, in combination with Afinitor (everolimus) for the treatment of patients with advanced...
Eisai Co., Ltd.has announced the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house...
Novartis Pharmaceuticals Corporation announced an agreement with Eisai Inc. to collaborate on commercial and certain medical affairs activities in the...
Eisai announced that its European regional headquarters Eisai Europe Ltd. has received license from the European Commission for anticancer agent...
Bristol Myers Squibb announced the Phase III CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis.
Eisai Co.,Ltd. announced that the FDA has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S....
The German Institute for Quality and Efficiency in Health Care (IQWiG) has published a report which concludes that an additional...